Phrenology once convinced people you could explain the mind by reading bumps on a skull. Cute idea, terrible science. Cancer research has its own version of that mistake when we treat a tumor like it is just a pile of rogue cells and forget the whole miserable workplace around it. This paper argues that one of the busiest trouble spots is the endoplasmic reticulum, or ER - the cell’s protein-folding factory - and when that factory gets jammed, the immune system can end up fighting cancer with one hand tied behind its back [1].
The Cell’s Overworked Shipping Department
Your cells make an absurd number of proteins, and many of them need to be folded just right before they go anywhere useful. The ER handles a lot of that work. When conditions get ugly - low oxygen, too few nutrients, too much oxidative stress, the usual tumor-microenvironment chaos - proteins start piling up half-baked. That sets off ER stress, and the cell launches the unfolded protein response, or UPR, through three main sensors: IRE1alpha, PERK, and ATF6 [1,2].
In normal life, that response is basically quality control. Slow production. Fix the mess. Try not to die.
In a tumor, though, the whole system gets weird. Cancer cells use ER stress like a sketchy company uses “temporary restructuring” - officially it is about survival, but somehow the employees doing the real work get squeezed. The stressed tumor adapts, keeps growing, and becomes harder to kill. Meanwhile, immune cells entering that neighborhood can also get warped by the same pressure cooker [1-3].
Why Your Immune Cells Start Acting Like Burned-Out Coworkers
This is the part that makes the review interesting. It is not just saying stressed cancer cells are tougher. It is saying ER stress can actively sabotage antitumor immunity.
Prior work has shown that in tumors, dendritic cells can get pushed into a state where they handle fats badly and lose some of their ability to present tumor antigens to T cells. That is a huge problem, because antigen presentation is how the immune system basically says, “Hey, security, this guy is absolutely not on the guest list” [2,4]. T cells can also get dragged into dysfunctional states under chronic stress, including impaired energy use and weaker effector function [3,4]. On top of that, ER stress signaling can reshape macrophages and other myeloid cells so they become more helpful to the tumor than to you, which is a rude plot twist but a very on-brand one for cancer biology [2-4].
The new 2026 review pulls those threads together into one bigger point: ER stress is not background noise. It may be part of the machinery behind immunotherapy resistance itself [1].
That matters because immune checkpoint drugs work beautifully for some patients and then completely ghost others. If T cells are the security team, many tumors have figured out how to lock the front door, cut the cameras, and hand the bouncer a nap schedule.
Why This Could Matter in the Real World
If these mechanisms keep holding up, ER stress pathways could become useful targets in combination therapy. Instead of only trying to step on the gas with immunotherapy, researchers may also need to stop the tumor from filling the engine with sand.
There is already preclinical evidence pointing that way. In a 2024 prostate cancer study, blocking IRE1alpha changed the tumor microenvironment, reduced tumor-associated macrophages, and improved response to anti-PD-1 therapy in mouse models [5]. Recent reviews also note that drugs aimed at UPR components are moving through early clinical testing, which means this field is no longer just lab-bench philosophizing over sad coffee and another failed blot [2].
That does not mean we are about to solve immunotherapy resistance next Tuesday. Stress signaling is tangled into normal cell biology, so hitting it carelessly could backfire. Immune cells use the UPR too. You do not want to “fix” the tumor by kneecapping the T cells you were counting on. Biomarkers will matter here. Dose will matter. Timing will matter. Cancer, as always, refuses to behave like a clean schematic in a grant figure [1,3].
The Big Takeaway
The clever part of this paper is that it reframes ER stress as a shared problem across the whole tumor ecosystem. Not just cancer cells. Not just immune cells. The whole stressed-out neighborhood.
That is useful because it explains something oncologists and patients already know all too well: getting the immune system into a tumor is not the same as getting it to win there. A T cell can show up and still be metabolically frazzled, poorly activated, or functionally boxed out. If researchers can learn when ER stress is helping the tumor most, they may be able to combine stress-targeting drugs with immunotherapy in a way that makes resistant tumors less smug and more vulnerable.
Which, frankly, would be a nice change of pace.
References
-
Zhao Y, Shang Y, Luan T, Yu Z, Yue Y, Niu X, Li H, Wang S, Wang C, Liu L. Endoplasmic reticulum stress in antitumor immunity and immunotherapy resistance: mechanisms and therapeutic implications. Molecular Cancer. 2026. DOI: https://doi.org/10.1186/s12943-026-02674-x
-
Cubillos-Ruiz JR and colleagues. Endoplasmic reticulum stress responses in anticancer immunity. Nature Reviews Cancer. 2025. DOI: https://doi.org/10.1038/s41568-025-00836-5 PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC12486299/
-
Di Conza G, Ho PC, Cubillos-Ruiz JR, Huang SCC. Control of immune cell function by the unfolded protein response. Nature Reviews Immunology. 2023;23(9):546-562. DOI: https://doi.org/10.1038/s41577-023-00838-0
-
Salvagno C, Mandula JK, Rodriguez PC, Cubillos-Ruiz JR. Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity. Trends in Cancer. 2022;8(11):930-943. DOI: https://doi.org/10.1016/j.trecan.2022.06.002
-
Thomsen MK and colleagues. Targeting IRE1alpha reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer. Nature Communications. 2024;15:8895. DOI: https://doi.org/10.1038/s41467-024-53039-1
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.